focus -WSS

focus

author：Wikipedia 2025-08-19 15:02:19 - browse：61

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Adopting new red light myopia treatments may be short

hotspot

WSS

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Readout LOUD: Venture capital, Gilead, and more M&A

Ahead of JPM, here's who's profiting most in health care

Surgery pushed Ben Carson to fame

Devoted Health’s losses in Medicare Advantage persist

J&J to buy cancer drug developer Ambrx Biopharma

hotspot

focus

focus

Medicare proposal to cover medical devices draws a mixed reaction

U.K. sequencing study surfaces new findings about tumor DNA

Trump demands the U.S. pay no more for drugs than other countries … again

340B reform proposal comes out of Senate working group

Anesthesiologist group: stop taking Ozempic before surgery

Why CTE doesn’t keep Americans from enjoying the Super Bowl

DIEP, the 'gold standard' of breast reconstruction, is under threat

Chronically ill young patients struggle to find fertility info

Medical records are filled with copy

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

hotspot

Feng Zhang, Grail founder join forces on new gene editing startup

A single drug, study failures leave Anavex with nothing but cash

Videos point to link between seizures and unexplained toddler deaths

AI gets buy

The FDA must approve intranasal treatments for anaphylaxis

What’s missing from the debate over nursing home staff minimums

explore

hotspot

knowledge

leisure time